Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

242
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
242
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026
Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026
Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026
Same author

Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa.

American journal of hematology·2026
Same author

Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies.

American journal of hematology·2026
Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026
Same journal

Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.

Blood global hematology·2026
Same journal

Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries.

Blood global hematology·2026
Same journal

Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi.

Blood global hematology·2026
Same journal

Clinical integration of red cell genotyping in children with β-thalassemia major: a prospective observational study.

Blood global hematology·2026
Same journal

Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.

Blood global hematology·2026
Same journal

Asian-type DEL among D-negative patients and donors in Malaysia can ease the demand for D-negative red cells and RhIG.

Blood global hematology·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K

Hidroxiurea para disminuir el riesgo de accidente cerebrovascular en niños con anemia de células falciformes: una

Emmanuela E Ambrose1, Paul Alikado Sabuni2, Don P Jason Iii3

  • 1Department of Pediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.

Blood global hematology
|December 24, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La hidroxiurea reduce eficazmente el riesgo de accidente cerebrovascular en niños con anemia de células falciformes (ACF) al disminuir las velocidades anormales del flujo sanguíneo. Este tratamiento es una alternativa viable a las transfusiones, especialmente en áreas con recursos limitados.

Palabras clave:
anemia de células falciformeshidroxiureaaccidente cerebrovascularvelocidad Doppler transcranealhematología pediátrica

Más Videos Relacionados

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

Videos de Experimentos Relacionados

Last Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

Área de la Ciencia:

  • Hematología pediátrica
  • Neurología
  • Farmacología

Sus antecedentes:

  • La anemia de células falciformes (ACF) es un trastorno hereditario que provoca accidentes cerebrovasculares en niños.
  • La ecografía Doppler transcraneal (TCD) evalúa el riesgo de accidente cerebrovascular en pacientes con ACF.
  • La prevención actual de accidentes cerebrovasculares incluye transfusiones, que tienen limitaciones en entornos con recursos limitados.

Objetivo del estudio:

  • Revisar sistemáticamente la eficacia de la hidroxiurea en la reducción de las velocidades de TCD y el riesgo de accidente cerebrovascular en niños con ACF.
  • Aclarar el tamaño del efecto y la duración del impacto de la hidroxiurea en las velocidades de TCD.

Principales métodos:

  • Se realizó una revisión sistemática de ensayos clínicos prospectivos en cinco bases de datos médicas importantes.
  • Los ensayos incluidos reclutaron niños con ACF, utilizaron cribado TCD y recopilaron datos de velocidad TCD y incidencia de accidentes cerebrovasculares durante la terapia con hidroxiurea.
  • Se analizaron datos de 13 ensayos en los que participaron 592 participantes.

Principales resultados:

  • La hidroxiurea disminuyó significativamente las velocidades medias de TCD en -30 cm/s durante 0.5 a 2.6 años, con normalización en la mayoría de los niños.
  • La incidencia de accidentes cerebrovasculares fue baja (0.52-1.92 por 100 pacientes-año) y ocurrió solo en aquellos con valores de TCD persistentemente altos (>200 cm/s).
  • La hidroxiurea demostró ser eficaz en la reducción de las velocidades de TCD y el riesgo asociado de accidente cerebrovascular.

Conclusiones:

  • La hidroxiurea es una estrategia eficaz para mitigar el riesgo de accidente cerebrovascular en la ACF pediátrica al reducir las velocidades de TCD.
  • Presenta una alternativa factible a las transfusiones de sangre, particularmente beneficiosa en entornos de atención médica con recursos limitados.
  • Se necesita más investigación para optimizar la dosificación, evaluar la seguridad a largo plazo y evaluar los beneficios integrales en diversas poblaciones.